COMP <GO>
TGTX vs SYRE // 10Y YIELD & FRED MACRO BETA
TG Therapeutics Inc. (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TGTX 6
— SYRE 3
▲ 10Y YIELD & FRED MACRO BETA LEADER: SYRE
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
macro-sensitivity
0.87
LAST: $95.51 (-1.09%) • MKT CAP: $10.08B
macro-sensitivity
0.89
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. SYRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | SYRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | -20.00% | +32.00 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | -1.64% | +1.36 | TGTX | /fcf-yield <GO> |
| Operating Margin | 20.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 17.60% | +69.70 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 26.00 | -13.08 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | TGTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.7 | 57.3 | +7.40 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.87 | 0.89 | -0.02 | SYRE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 22.0x | -5.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.36B | $10.08B | -$717.5M | SYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | SYRE REV | TGTX GROSS % | SYRE GROSS % | TGTX FCF | SYRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $586.8M | 83.7% | — | -$25.0M | -$169.3M |
| FY 2024 | $329.0M | $584.0M | 88.3% | — | -$40.6M | -$157.4M |
| FY 2023 | $233.7M | $886.0K | — | — | -$41.9M | -$99.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
SYRE // BETA 0.89